Source: Pharmacy Times articles
Two abstracts from ASCO demonstrate that pre-treatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.
Read More